Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04484441
Other study ID # 19-011382
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date March 24, 2022
Est. completion date December 2024

Study information

Verified date February 2024
Source Mayo Clinic
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Performing surgery in utero on fetuses with certain birth defects has led to significant improvements in outcomes after birth; however, many of these infants are born preterm which can decrease the effectiveness of these procedures. The investigators aim to understand the effects of surgery on the maternal and fetal immune system and whether immune activation may be causing some of these infants to be born prematurely.


Description:

Over 300,000 neonates worldwide die in their first month of life due to a congenital birth defect. Thanks to advancements in diagnostic technology and imaging, the field of fetal surgery was developed to treat some of these conditions in utero. Results have demonstrated improved short and long-term outcomes following surgery, especially for those fetuses diagnosed with congenital diaphragmatic hernia, lower urinary tract obstruction and spina bifida. However, over 30% of the surgical cases will have preterm labor, leading to complications related to neonatal prematurity. The cause of this surgery-induced preterm birth is unknown; however, disruption in fetal-maternal tolerance may lead to immune activation and inflammation of the maternal and fetal immune systems. Maintaining immunologic tolerance is essential during pregnancy, as a women shares only half of her genetic material with the fetus. Previous work has demonstrated that fetal surgery leads to an increase in maternal cells identified in cord blood. Animal studies have also shown that in utero intervention leads to the activation of maternal cells against fetal (paternal) antigen. Based on this previous data, it is hypothesized that surgical trauma following in utero intervention results in mixing of maternal and fetal cells leading to activation of systemic (adaptive maternal immunity) and regional (fetal placental macrophages) immune responses that disrupt fetal-maternal tolerance, which can result in preterm birth. Blood will be collected from pregnant women and their partners. Blood and placental tissue will be collected from infants that do and do not undergo in utero surgery to determine whether maternal T cells specific to fetal antigen are activated and expand after in utero intervention; and 2) to determine whether placental macrophages (Hofbauer Cells) and histology in the maternal-fetal interface exhibit increased activation and inflammation in surgical cases born preterm (<37 weeks) compared to term. Should this exploratory study reveal activation of maternal and/or fetal immune responses following in utero surgery, modalities aimed at therapeutically suppressing these acute responses may prolong gestation, significantly benefiting newborns diagnosed with a congenital anomaly.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 60
Est. completion date December 2024
Est. primary completion date July 2024
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria for study group: - Maternal age =18 years - Pregnant with a congenital anomaly diagnosis AND undergoing fetal intervention in utero - Delivery planned at Mayo Clinic, Rochester MN Inclusion Criteria for control group: - Maternal age =18 years - Pregnant with normal ultrasound findings - Delivery planned at Mayo Clinic, Rochester MN Exclusion Criteria: - Delivery planned elsewhere - Abnormal fetal karyotype

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Blood and placenta specimen collection.
Collection of maternal and paternal blood. Collection of infant cord blood and placenta.

Locations

Country Name City State
United States Cincinnati Children's Hospital Medical Center Cincinnati Ohio
United States University of Texas Houston Houston Texas
United States Mayo Clinic in Rochester, Minnesota Rochester Minnesota

Sponsors (1)

Lead Sponsor Collaborator
Mayo Clinic

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Maternal T cell activation following in utero intervention. T cells from maternal blood will be isolated and CDR3 spectra typing will be completed. These samples will be compared to each other to identify high frequency T cell clones as well as longitudinal changes in the dynamics of clones.
Blood collected at the four time points above will be profiled for changes in immune activation using mass cytometry (CyTOF) and plasma collected to measure changes in cytokine responses pre- and post-surgery by multiplex.
Baseline, 1-2 days post intervention, 1 week post intervention, delivery
Secondary Placental histology in the maternal-fetal interface in term and preterm fetal intervention cases Placental macrophages will be phenotyped for subtypes (M1 classical versus M2 repair), activation (CD25 and CD40), and apoptosis status by CyTOF. Comparisons will be made between those born before 37 weeks and those born after 37 weeks in the surgical group, as well as to those who didn't undergo surgery.
From each placenta, 5 sections will be dissected and submitted for histological evaluation of placental villitis. Toxoplasmosis, Other [syphilis, varicella-zoster, parvovirus B19], Rubella, Cytomegalovirus and Herpes (TORCH) infection panels will be completed to distinguish infectious villitis from immune-mediated villitis.
Delivery
See also
  Status Clinical Trial Phase
Recruiting NCT06065995 - StoMakker Mobile Application N/A
Not yet recruiting NCT06007885 - Examining Capacity Building of Youth With Physical Disabilities to Pursue Participation Following the PREP Intervention. N/A
Completed NCT02854150 - Improving Genetic Counseling for Patients With Spina Bifida Using Next Generation Sequencing
Completed NCT00655681 - Prevention of Post Operative Bone Loss in Children N/A
Completed NCT00378664 - Lumbar to Sacral Ventral Nerve Re-Routing Phase 2
Active, not recruiting NCT00891891 - Psychosocial Adjustment of Adolescents With Spina Bifida
Active, not recruiting NCT00031122 - Study of Genetic Risk Factors for Spina Bifida and Anencephaly N/A
Completed NCT03573726 - Use of a Diurnal Indwelling Urethral Catheter to Improve Quality of Life N/A
Completed NCT03851107 - The Effectiveness of Participation-focused Interventions on Body Functions of Youth With Physical Disabilities N/A
Not yet recruiting NCT03698721 - Urothelium Tissue Engineering Using Biopsies From Transurethral Resection of Prostate
Recruiting NCT02938130 - The Impact of Community-based Wellness Programs on The Triple Aim N/A
Recruiting NCT02592291 - Mobile Health Self-Management and Support System for Chronic and Complex Health Conditions N/A
Not yet recruiting NCT05784285 - Downstream Effects of Personalized 'Top-down' Participation-based Interventions Among Youth With Physical Disabilities N/A
Completed NCT00720161 - Metformin in Children With Motor Deficit N/A
Completed NCT05861024 - Urinary Calculi After Bladder Augmentation in Children
Completed NCT05858840 - Urinary Artificial Sphincter in Children
Recruiting NCT04362592 - In-Utero Endoscopic Correction of Spina Bifida N/A
Recruiting NCT03856034 - Laparotomy Versus Percutaneous Endoscopic Correction of Myelomeningocele N/A
Enrolling by invitation NCT04186130 - Fecal Microbium Change in Pediatric Patients With Spina Bifida: Prospective Case-control Study
Active, not recruiting NCT05117827 - Pediatric Powered Wheelchair Standing Devices: An Exploratory Study N/A